Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib SC vs IV in relapsed/refractory multiple myeloma (China)
CTR20160359Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2016
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Aug 2016; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20160359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160359.